highly variable drugs-Cmax [Regulatives / Guidelines]

posted by nuka2020 – United Arab Emirates, 2020-11-19 11:09 (175 d 09:27 ago) – Posting: # 22067
Views: 961

According to the GCC guidelines a wider range of Cmax(i.e 75-133%) can be acceptable for HVDP, where it has been demonstrated that the within- subject variability for Cmax of the reference compound in the study is >30%.
But, i have a study which was performed as per Eu guidelines and accordingly, the acceptance criteria for Cmax can be widened to a maximum of 69.84 – 143.19%. Accordingly, the results of Cmax is: 70.46%-141.90%
Need suggestion whether this studies can be acceptable as per GCC guidelines?? :confused::confused:

Complete thread:

 Admin contact
21,460 posts in 4,486 threads, 1,511 registered users;
online 4 (0 registered, 4 guests [including 4 identified bots]).
Forum time: Thursday 21:37 CEST (Europe/Vienna)

Nothing in the world is more dangerous
than sincere ignorance
and conscientious stupidity.    Martin Luther King, Jr.

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz